An interventional study of nutritional intervention in Obesity; Drug, sponsored by Ariel University. Completed at 3 sites in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Ariel University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Obesity with a site in Israel — 22 open to participants now, 29 under way, 16 of them phase 3. Obesity · Israel.
Among the 128 studies in Obesity with a site in Israel, this one is the 51st largest by enrollment of the 98 interventional ones that give a count, is one of 8 that started in 2025, is one of 55 with no phase, and was the 106th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →22 of the 128 studies in Obesity with a site in Israel are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Israel, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Israel, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Israel, United States, Argentina and 24 more countries
Ages 18+
Eli Lilly and Company · Sites in Israel, United States, Australia and 11 more countries
Ages 18+
Assaf-Harofeh Medical Center · Sites in Israel
Ages 18+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 29 · Phase 4 4
First in 2004; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 128 across the 98 interventional studies, 82 across the 29 observational. Of the 65 that completed or were terminated, 15 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 128 have an industry lead sponsor. The 10 most frequent:
Ariel University is the lead sponsor of 29 studies on the registry; 6 are open to participants now.
Ariel University has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
7 of the studies in Obesity with a site in Israel that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT06439277Phase 3Eli Lilly and CompanyA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | 2027-10 |
| NCT06681246Weizmann Institute of ScienceThe Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment | 2026-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 128 studies in Obesity with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to evaluate the effect of nutrition intervention on gastrointestinal symptoms, treatment discontinuation rate, nutritional parameters (e.g., dietary intake and eating habits), anthropometric measures, functional parameters, and QOL during the initiation and up-titration phase of incretin-based Anti Obesity Medications (AOM) treatment in patients with overweight/obesity.
The nutrition intervention protocol will be developed based on literature review, focus groups with health care professionals, and patient interviews.
A single-center pilot study will be performed at the Tel-Aviv Assuta Medical Center, among 10 patients who are about to initiate long-term weight management treatment with Wegovy© (semaglutide 2.4 mg), followed by a multi-center, parallel design open-label, RCT, which will be conducted at the Tel-Aviv Assuta Medical Center and Rabin Medical Center - Beilinson Hospital, in 120 patients who are about to initiate long-term weight management treatment with Wegovy© or Mounjaro© .
The intervention group will receive nutrition guidance before AOM treatment by registered dietitian (RD) followed by nutrition and behavioral recommendations according to reported gastrointestinal symptom(s). The control group will receive the usual nutrition care for patients treated with AOM.
Primary outcomes (gastrointestinal symptom assessment) and secondary outcomes (incretin-based AOM discontinuation rate, nutritional parameters, anthropometrics, functional parameters and QOL) will be evaluated by interviews, questionnaires and measurements at baseline, at the end of Wegovy© or Mounjaro© titration phase [20 weeks (T1)] and weekly during the study period (for GI symptoms assessment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition, participants who decide not to initiate or stop Wegovy© or Mounjaro© treatment for more than two consecutive injections for any reason or who undergo bariatric surgery or endoscopic sleeve gastroplasty during the study period will be excluded from the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nutrition guidance before AOM treatment by registered dietitian (RD) followed by nutrition and behavioral recommendations according to reported gastrointestinal symptom(s).
Behavioral: nutritional intervention
* Usual nutrition care treatment for patients treated with Wegovy© or Mounjaro© (RCT). * Prior to the initiation of AOM treatment, participant will receive general nutrition guidance based on national recommendations according to the Mediterranean diet.
A nutrition guidance before initiation of AOM treatment include recommendations for food choices and eating habits to minimize the occurrence and severity of GI symptoms during the up-titration phase, will be given by registered dietitian (RD) from the study team. Next, each week, participants will provide weekly reports of GI symptoms occurrence and severity, by responding to queries sent via WhatsApp/SMS and for occurring symptoms, an automatically structured nutrition and behavioral treatment recommendations will be sent . If participants expressed an interest in personalized dietary guidance on this matter, the study team RD will contact him/her by telephone, within a range of 48 hours, to provide individualized recommendations. Three days after each report of GI symptom(s), participants will receive an additional message and will be asked to report the occurrence and severity of the GI symptom, and their compliance with the specific dietary instructions received.
Gastrointestinal symptoms assessment
GI symptoms rating scale (GSRS) - assess the degree of specific GI complaints Every question is rated by seven graded Likert-type scale (1 represents the absence of troublesome symptoms and 7 represents very troublesome symptoms) while a higher score of the whole questionnaire and by dimension represents more severe symptoms.
Time frame: Baseline and at the end of the study period (20 weeks)
Defecation texture
Bristol stool scale - classifying the form of human feces into seven categories. Type 1-2 are considered abnormal hard stools and indicative of constipation type, and type 5-7 are considered abnormally loose/liquid stools and indicative of diarrhea or urgency
Time frame: Baseline and at the end of the study period (20 weeks)
Bowel Movement (BM) frequency
will be assessed according to five acceptable categories: \>3 BMs/day, 2-3 BMs/day, 1-2 BMs/day, 3-4 BMs/week, \<3 BMs/week
Time frame: Baseline and at the end of the study period (20 weeks)
Participants gastrointestinal symptoms report
Participant subjective and objective reporting of GI symptoms
Time frame: Baseline, at the end of the study period (20 weeks) and weekly until 20 weeks (for subjective GI symptoms report only)
Incretin-based AOM treatment discontinuation rate
Time frame: At the end of the study period (20 weeks) and weekly until 20 weeks
Anthropometric measures - weight
Weight (kg) by digital scale
Time frame: Change from baseline at the end of the study period (20 weeks)
Anthropometric measures - waist circumference (WC)
will be measured by tape measure (cm)
Time frame: Change from baseline at the end of the study period (20 weeks)
Body composition - fat mass (kg)
Body composition analysis using Inbody370S®
Time frame: Change from baseline at the end of the study period (20 weeks)
Dietary intake
24-hour dietary recall (24HR)
Time frame: Change from baseline at the end of the study period (20 weeks)
Eating habits assessment
General questions regarding eating patterns, hydration and foods intolerance
Time frame: Change from baseline at the end of the study period (20 weeks)
Eating habits assessment - Control of Eating
Control of Eating Questionnaire (CoEQ) - The of CoEQ consists of 21 items (19 questions are rated by 100 mm VAS, and two question are open-ended). Greater score represents greater levels of Craving Control.
Time frame: Change from baseline at the end of the study period (20 weeks)
Functional parameters - muscle strength
Handgrip (HG) muscle Strength - measure static muscle strength (kg) of the upper extremities by a digital hand dynamometer (Jamar plus digital©)
Time frame: Change from baseline at the end of the study period (20 weeks)
Functional parameters- leg strength and endurance
30-seconds sit and stand test - counts the number of times the patient stands in 30 seconds. Higher scores means a better outcome.
Time frame: Change from baseline at the end of the study period (20 weeks)
Quality of life assessment
EQ-5D-3L questionnaire -include the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS) .The EQ-5D-3L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems.The EQ VAS records the patient's self-rated health. Participants will be asked to subjectively rate their overall state of health by using a 0 to 100 VAS, with a higher score reflects a better outcome.
Time frame: Change from baseline at the end of the study period (20 weeks)
Eating habits assessment - Food preferences
Leeds Food Preference Questionnaire (LFPQ). The questionnaire involves an explicit evaluation of "liking" and "wanting" for 16 food items that can be categorized as high-fat savory (HFSA), low-fat savory (LFSA), high-fat sweet (HFSW) and low-fat sweet (LFSW). Each food image is scored on a 100-mm VAS, while a higher score indicates a stronger preference for that food category. The second sub-task evaluates "implicit wanting" and requires rapid choice between 96 paired combinations of the food images from different categories
Time frame: Change from baseline at the end of the study period (20 weeks)
Anthropometric measures - height (cm)
(cm) by altimeter
Time frame: Change from baseline at the end of the study period (20 weeks)
Body composition- percentage of body fat (BF%)
Body composition analysis using Inbody370S®
Time frame: Change from baseline at the end of the study period (20 weeks)
Body composition - fat-free mass (kg)
Body composition analysis using Inbody370S®
Time frame: Change from baseline at the end of the study period (20 weeks)
Body composition - skeletal muscle mass (kg)
Body composition analysis using Inbody370S®
Time frame: Change from baseline at the end of the study period (20 weeks)
Biochemical tests
Participants will be asked to provide at T0 biochemical tests obtained during the last 3 months, including complete blood count, lipid profile, fasting glucose, HbA1c, iron, transferrin, ferritin, vitamin B12, folate, vitamin D, albumin and total protein
Time frame: At baseline
Demographics - age
years
Time frame: At baseline
Demographics - marital status
married, single, divorced or widowed
Time frame: At baseline
Demographics - education
less than high school, high school graduate, high school diploma, bachelors degree, masters degree, MD or doctoral degree
Time frame: At baseline
Demographics - occupation status
employee full time, employee part time, self-employed or other
Time frame: At baseline
Health status - Number of participants with coexisting medical conditions and their types
T2DM, prediabetes, dyslipidemia, HTN,sleep apnea, orthopedic problems, GERD, mental disorder or other
Time frame: Baseline and at the end of the study period (20 weeks)
Number of participants using regular medications and their types
usual medications
Time frame: Baseline and at the end of the study period (20 weeks)
Smoking habits
smoker, former smoker or never
Time frame: Baseline and at the end of the study period (20 weeks)
Number of participants using supplementation and their Types
multiviamin, Iron, vitamin D, folic acid, vitamin B12, calcium or other
Time frame: Baseline and at the end of the study period (20 weeks)
Lifestyle factors - Sleeping habits
sleeping quality on a scale of 0-3 (0- very good, 1-quite good, 2- quite bad, 3- very bad)
Time frame: Baseline and at the end of the study period (20 weeks)
Lifestyle factors - frequency of physical activity
number of exercises per week
Time frame: Baseline and at the end of the study period (20 weeks)
Lifestyle factors - duration of physical activity
exercise time in minutes
Time frame: Baseline and at the end of the study period (20 weeks)
Lifestyle factors - type of physical activity
aerobic or anaerobic
Time frame: Baseline and at the end of the study period (20 weeks)
Ran from Jan 2025 to primary completion in Aug 2026, 18 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 18 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Feb 2026 → Aug 2026 and completion Mar 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ariel University